In vivo, PTPN22 ablation ameliorated aortic valve lesions in a wire injury-induced CAVD mouse model, validating the pathogenic role of PTPN22 in CAVD. This evidence concerns the gene PTPN22 and congenital bilateral aplasia of vas deferens from CFTR mutation.